Johnson & Johnson Stock Price, News & Analysis

Pyramid Biosciences has appointed Dr. Nushmia Khokhar as the new Chief Medical Officer to lead the company's clinical pipeline advancements. Dr. Khokhar, previously with Umoja Biopharma and Autolus Therapeutics, brings extensive experience in oncology clinical development. The CEO, Brian Lestini, expressed confidence in her leadership during this growth phase. Dr. Khokhar's background includes significant roles at Johnson & Johnson, where she directed successful clinical trials for cancer therapies. Pyramid Biosciences focuses on creating precision therapies for serious diseases.

Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA, on September 7. Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech, will represent the company in a session set for 11:00 a.m. (Eastern Time). Investors can access the conference call via the Johnson & Johnson website. A webcast and podcast replay will be available roughly 48 hours post-event.

Johnson & Johnson (NYSE: JNJ) reported a 3.0% increase in total sales to $24.0 billion for Q2 2022, with operational growth of 8.0%. Adjusted earnings per share (EPS) rose 4.4% to $2.59, despite a 23.4% drop in diluted EPS to $1.80. The company maintains its 2022 guidance, reflecting resilience amid economic challenges. Regional growth was driven by Pharmaceutical sales, which surged 12.4%, while Consumer Health and MedTech faced declines. Currency fluctuations impacted reported results.

Johnson & Johnson (NYSE: JNJ) announced the retirement of Michael Ullmann as Executive Vice President and General Counsel after 33 years of service. Ullmann will be succeeded by Elizabeth Forminard, effective October 17, 2022. Forminard brings extensive experience from her previous roles in the Pharmaceutical, MedTech, and Consumer Health sectors, and will also join the Executive Committee. Ullmann's tenure is noted for his focus on diversity, equity, and inclusion, guiding the company through complex legal matters. The transition reflects the company's commitment to strong leadership.

Johnson & Johnson (NYSE: JNJ) has launched its first Satellite Center for Global Health Discovery at Duke-NUS Medical School in Singapore. This center focuses on combating flaviviruses like dengue, which affects 400 million people annually and poses a rising threat due to climate change. The initiative builds on a decade of collaboration with Duke-NUS and aims to accelerate research for antiviral treatments. The center also incorporates the Global Health Discovery QuickFire Challenge with a $300,000 funding pool to encourage innovative solutions for flavivirus diseases.

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive VP and Worldwide Chairman of Pharmaceuticals, will represent the company during a session at 1:00 p.m. (Eastern Time). Interested investors can access the live webcast on the Johnson & Johnson website, and a replay will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) has appointed Thibaut Mongon as CEO Designate and Paul Ruh as CFO Designate for its upcoming New Consumer Health Company, set to separate in 2023. This transition aims to enhance focus and growth for both the new entities, following a strategy announced in November 2021 to address industry-specific needs. Mongon, with over 20 years at JNJ, has led significant consumer health innovations, while Ruh brings extensive financial experience from his tenure in the consumer goods sector. The separation is anticipated to unlock value and improve operational agility.

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 38th Annual Strategic Decisions Conference on June 1, 2022, at the New York Hilton Midtown. The CEO, Joaquin Duato, will represent the company during a session at 10:00 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live event.